By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Israel and Lebanon's Hezbollah continue to trade attacks - 2Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- 3The Rhythms of the Street: Shipping's Tune in the Economy's Symphony
- 4This Week In Space podcast: Episode 189 — Privatizing Orbit
- 5Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- RFK Jr. says he's following 'gold standard' science. Here's what to know
- Sudan war ‘being fought on women’s bodies’: Survivors detail sexual assault
- Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children
- Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- Volcanic eruption led to the Black Death, new research suggests
- Israel launches new wave of attacks against Hezbollah in Beirut
- Going with Children: Tips for Tranquil Family Get-aways
- Chinese construction workers in Israel: 'I’d rather be bombed than live in poverty'
